Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of ($0.29), $0.31 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $153.88 million versus the consensus estimate of $144.94 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.